Pharmatech
Lilly's Triple-G Drug Just Hit 30.3% Weight Loss. Then the FDA Line Moved to 2027.
Lilly's triple-G shot retatrutide hit 30.3% weight loss in Phase 3 — surgery territory. Then the FDA filing slipped to Q1 2027 over manufacturing.
Topic
Obesity Drugs
The latest Obesity Drugs news and analysis from Tech Arcade.
Biotech
Lilly's Triple-Threat Shot Just Melted 55 Pounds — and Notched Its Fifth Phase 3 Win
Eli Lilly's triple-agonist shot retatrutide hit 22.6% weight loss in two more Phase 3 trials — its fifth straight win, with an FDA filing due Q1 2027.